Navigation Links
Tongjitang Chinese Medicines Company Reports Second Quarter 2010 Financial Results
Date:8/18/2010

ation of using these non-GAAP financial measures is that these non-GAAP measures exclude share-based compensation expenses that have been and will continue to be significant recurring expenses in the Company's business for the foreseeable future. Reconciliations of the Company's non-GAAP financial data to the most comparable GAAP data are included at the end of this press release.

About Tongjitang Chinese Medicines Company

Tongjitang Chinese Medicines Company, through its operating subsidiaries Tongjitang Pharmaceutical, Tongjitang Distribution, Tongjitang Chain Stores, Guizhou Long-Life Pharmaceutical Company Limited, Qinghai Pulante, Anhui Jingfang and Gui Liqour Ltd., is a vertically integrated specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China. Tongjitang's principal executive offices are located in Shenzhen, China.

Tongjitang's flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi. In addition to Xianling Gubao, the Company manufactures and markets 35 other modernized traditional Chinese medicine products and 36 western medicines. Please visit http://www.tongjitang.com for more information.

Safe Harbor Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, they cannot assure you that their expectat
'/>"/>

SOURCE Tongjitang Chinese Medicines Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Tongjitang Files 2009 Annual Report on Form 20-F
2. Tongjitang Chinese Medicines Company Reports First Quarter 2010 Financial Results
3. Tongjitang Chinese Medicines Acquires Guiyang Liquor Factory
4. China Medical Technologies Announces the Use of its HER-2 FISH Probe in a Cancer Targeted Therapy Research Project Sponsored by the Chinese Ministry of Health
5. China BCT Signs Exclusive Distribution Contract With Liujiang County Chinese Medicine Hospital
6. Biosites Triage Products Seized by Beijing Customs; Chinese Market Facing Shortage
7. China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology
8. Chinese Distribution Contract Extended for an Additional 4 Years
9. Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril
10. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
11. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014  Lockton Dunning Benefits, the ... Companies, announced the addition of Vice President ... Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... industry experience to the position.  Most recently, she ... at Diplomat Specialty Pharmacy, where she has held ...
(Date:12/24/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... that the Company achieved the Public Notice (Gong ... certificate of TPI,s Qionglai Facility (QLF) from the ... notice period is a significant procedure of GMP ...
(Date:12/24/2014)... and RALEIGH, N.C. , Dec. ... Endo International plc (NASDAQ: ENDP ) (TSX: ... BDSI ) announced today that they have submitted a ... to the U.S. Food and Drug Administration (FDA).  Buprenorphine ... of pain severe enough to require daily, around-the-clock, long-term ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... 2012 /PRNewswire-Asia-FirstCall/ -- ShangPharma Corporation (NYSE: SHP ... pharmaceutical and biotechnology research and development outsourcing company, ... report on Form 20-F for the year ended ... and Exchange Commission (the "SEC"). The annual report ...
... Mindray Medical International Limited (NYSE: MR ), ... worldwide, announced today that it has filed with the ... 20-F that included audited financial statements for the year ... Annual Report on Form 20-F is available on Mindray,s ...
Cached Medicine Technology:ShangPharma Corporation Files 2011 Annual Report on Form 20-F 2Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2
(Date:12/26/2014)... (PRWEB) December 26, 2014 Plugin and template ... TransPack Volume 5 Plugin for Final Cut Pro X. , ... hard light tool to pull off an industry professional look” ... get their hands on TransPack Volume 5, a new level ... is a set of over 50 Final Cut Pro X ...
(Date:12/26/2014)... 2014 Pentec Health, Inc. number fourteen ... of Pennsylvania for 2014. The awards program, created in ... its kind in the country. The program is a ... of Community and Economic Development, the Pennsylvania State Council ... Central Penn Business Journal. , Charlie Wilson, ...
(Date:12/25/2014)... 2014 The microscopy market is ... to reach $5,756.0 million by 2019. Optical microscopy ... The electron microscopes product segment is expected to ... , Rising focus on nanotechnology, technological advancements, and ... microscopy market. , Get Full Copy of Report ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... “Every three months the trends for evening ... dress will be one of the hottest styles in the ... Today, the company releases 26 A-line sweetheart evening dresses, and ... , “We are trying our best to help a ... designs. Along with affordable prices, we provide discounted delivery costs ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... , , , ... of revenue and payment cycle management solutions for the ... Illinois, recently implemented the Emdeon Patient Responsibility Estimator(SM) solution. ... used by BroMenn,s patient access staff to inform patients ...
... , SAN ANTONIO, Aug. 24 Fall 2009 ... in family schedules, which can have a devastating impact on family pets ... season. PurinaCare(R) Pet Health Insurance ( www.purinacare.com ), which is committed to ... urging all pet owners to be aware of the signs of post-summer ...
... , , , ... VRX ) today announced preliminary results from its ... pain associated with postherpetic neuralgia (PHN), a painful and common complication ... did not meet its pre-specified primary efficacy endpoint. Further detailed analyses ...
... WACO, Texas, Aug. 24 Two professors at ... health care plan in their new book Health Care for ... University Press, that does not create a government entitlement program ... care of Americans who currently have coverage. , , ...
... WASHINGTON, Aug. 24 What did all the following businessmen have in common? , ... Merv Griffin (TV Producer) , Tom Witter ... , , They all died from the prostate cancer, ... son, father or grandfather will die from this disease. , , Hank ...
... NANJING, China, Aug. 24 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group,(NYSE: ... leading manufacturer and supplier,of branded generic and innovative pharmaceuticals ... University Cancer Center. , Located ... of,China,s renowned cancer research institutions, prominent in pre-clinical and,clinical ...
Cached Medicine News:Health News:Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency 2Health News:Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency 3Health News:Emdeon and BroMenn Healthcare System Take the Lead on Consumer Price Transparency 4Health News:Does Your Pet Have Post-Summer Separation Anxiety? 2Health News:Does Your Pet Have Post-Summer Separation Anxiety? 3Health News:Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN) 2Health News:Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN) 3Health News:Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN) 4Health News:Baylor University Economists Call for Different Tack on Health Care Insurance 2Health News:Prostate Cancer Kills - Every 20 Minutes; September Is Prostate Cancer Awareness Month 2Health News:Simcere Announces Strategic Partnership with Sun Yat-Sen University Cancer Center 2
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Severe revision options for the knee and hip...
Severe revision options for the knee and hip...
The Precedent establishes a new generation of revision hip stems....
Medicine Products: